See the DrugPatentWatch profile for Meperidine
How big is the meperidine (pethidine) drug market?
I can’t provide market size or revenue figures for meperidine from the provided information set. To answer this, I would need at least one of the following: a specific report/source you want used (e.g., IQVIA, EvaluatePharma, Fortune Business Insights) or any figures you already have (global vs. country, year, sales channel).
Which countries drive demand for meperidine?
Meperidine use varies widely by country because availability, prescribing practices, and safety restrictions differ. In many jurisdictions, its clinical use is more limited than in the past, which can reduce market demand compared with other opioid analgesics. Exact country shares require sales data from a source such as customs/IMS/health-claims datasets or a market research report.
What trends are shaping the meperidine market?
Key forces that typically move the market for older opioid analgesics include:
- Regulatory and safety scrutiny affecting prescribing and product availability
- Shifts toward other opioids and non-opioid pain management approaches
- Changes in hospital formularies and guideline-driven use
To quantify these trends for meperidine, the relevant regulator decisions and uptake data by year are needed.
Why might meperidine demand be declining in some places?
Meperidine has well-known safety limitations (especially concerns tied to metabolite accumulation in some patients). That tends to push clinicians and regulators toward alternatives, which can reduce utilization and therefore market sales. The exact effect on each market depends on local label restrictions, warnings, and enforcement.
What drugs compete with meperidine?
Meperidine competes with other opioid analgesics (used in similar settings like acute pain and procedural analgesia) and with multimodal pain regimens. The specific competitive set depends on the country’s formulary and what opioids are preferred by guidelines and regulators.
Is meperidine still widely marketed as a brand, or mostly generic?
In many older generics markets, products shift from brand to generic over time, and pricing compresses. Whether meperidine in your target geography is dominated by a few manufacturers versus many generics needs sourcing from drug registries or market datasets.
What regulatory and compliance issues affect sales?
Opioid sales are heavily shaped by:
- Controlled-substance scheduling and dispensing rules
- Labeling restrictions and required warnings
- Manufacturing and import controls
- Pharmacovigilance and risk-management requirements
A precise answer needs the country or region you care about.
Pricing and reimbursement: what drives meperidine costs?
Opioid pricing is usually driven by:
- Generic competition and procurement contracts (especially in hospitals)
- Tendering practices
- Reimbursement rules (where applicable)
Without a target market/region and a source, meperidine price comparisons can’t be stated accurately.
If you want an actionable market view, what details should you provide?
Tell me:
1) Global or a specific country/region
2) The timeframe (e.g., 2023-2028 forecast)
3) What you mean by “market” (manufacturers’ sales, pharmacy retail, or hospital procurement)
4) Whether you need branded vs. generic, or active ingredient only
With that, I can produce a focused market narrative (demand drivers, constraints, competition, and outlook) tailored to your target.
Sources
No sources were provided with the question, so no claims can be cited.